biotech – Karma https://karmaimpact.com Advancing people, planet and profit. Thu, 02 Apr 2020 07:10:27 +0000 en-US hourly 1 https://wordpress.org/?v=5.3.2 Will Impact Investors Be Spared the Wrath of COVID-19? /will-impact-investors-be-spared-the-wrath-of-covid-19/ /will-impact-investors-be-spared-the-wrath-of-covid-19/#respond Thu, 02 Apr 2020 10:00:00 +0000 /?p=15435 Impact investors with money in sectors such as biotech, health and communications technology may see pandemic-fueled growth. Forecasting models from a leading climate change stress-analysis firm suggest that share prices may be down as much as 38% this year from the end of 2019. While COVID-19’s long-term economic impact is uncertain, early scenario analysis suggests […]

The post Will Impact Investors Be Spared the Wrath of COVID-19? appeared first on Karma.

]]> /will-impact-investors-be-spared-the-wrath-of-covid-19/feed/ 0 CRISPR Passes In-Human Safety Test, Showing Promise for Gene-Editing Tool’s Role in New Medications /crispr-passes-in-human-safety-test-showing-promise-for-gene-editing-tools-role-in-new-medications/ /crispr-passes-in-human-safety-test-showing-promise-for-gene-editing-tools-role-in-new-medications/#respond Sat, 08 Feb 2020 02:08:59 +0000 /?p=14825 The gene-editing technique known as CRISPR was declared safe and feasible after a trial in cancer patients, potentially opening the door for the controversial tool’s wider use in fighting disease and improving health. The clinical trial, with just three patients, was designed simply to determine the safety of the technique, not to cure the disease. […]

The post CRISPR Passes In-Human Safety Test, Showing Promise for Gene-Editing Tool’s Role in New Medications appeared first on Karma.

]]> /crispr-passes-in-human-safety-test-showing-promise-for-gene-editing-tools-role-in-new-medications/feed/ 0 Biotech Epirium Raises $85M With Aim to Develop Anti-aging Technology /biotech-epirium-raises-85m-with-aim-to-develop-anti-aging-technology/ /biotech-epirium-raises-85m-with-aim-to-develop-anti-aging-technology/#respond Wed, 18 Dec 2019 21:55:55 +0000 /?p=14332 It may be the final frontier in medicine — slowing down or reversing the process of aging. Besides the promise of a longer life, it also means fortunes made — think Ponce de Leon and his search for the Fountain of Youth. Biotech company Epirium is pursuing that holy grail of medical research. The San […]

The post Biotech Epirium Raises $85M With Aim to Develop Anti-aging Technology appeared first on Karma.

]]> /biotech-epirium-raises-85m-with-aim-to-develop-anti-aging-technology/feed/ 0 Investors Seeing Green With Bets on Ag Biotech, as Key to Sustainable Agriculture, in 2020 /investors-seeing-green-with-bets-on-ag-biotech-as-key-to-sustainable-agriculture-in-2020/ /investors-seeing-green-with-bets-on-ag-biotech-as-key-to-sustainable-agriculture-in-2020/#respond Thu, 12 Dec 2019 22:30:31 +0000 /?p=14258 As the farm industry sparks worries about everything from genetically modified food to climate change, impact investors are increasingly betting on a post-chemical, sustainable future in agriculture.  Agriculture-related biotechnology, such as biofertilizer and microbiome, is seen as the most exciting thing for sustainable agriculture next year. Investors expect innovations in Ag Biotech to deliver better […]

The post Investors Seeing Green With Bets on Ag Biotech, as Key to Sustainable Agriculture, in 2020 appeared first on Karma.

]]> /investors-seeing-green-with-bets-on-ag-biotech-as-key-to-sustainable-agriculture-in-2020/feed/ 0 Biotech Novoheart to Collaborate With AstraZeneca on Heart-in-a-Jar Model /biotech-novoheart-to-collaborate-with-astrazeneca-on-heart-in-a-jar-model/ /biotech-novoheart-to-collaborate-with-astrazeneca-on-heart-in-a-jar-model/#respond Tue, 26 Nov 2019 21:49:14 +0000 /?p=13954 Stem cell biotech company Novoheart and pharmaceutical giant AstraZeneca announced they would be partnering to develop the first test tube model of human heart failure, also called heart-in-a-jar. The companies said they would use heart tissue engineered by Novoheart to emulate conditions faced by patients suffering from heart failure with preserved ejection fraction (HFpEF) and […]

The post Biotech Novoheart to Collaborate With AstraZeneca on Heart-in-a-Jar Model appeared first on Karma.

]]> /biotech-novoheart-to-collaborate-with-astrazeneca-on-heart-in-a-jar-model/feed/ 0 Google’s Porat Sees AI as Weapon in Breast Cancer War, as CFO Discusses Her Struggle With Disease /googles-porat-sees-ai-as-weapon-in-breast-cancer-war-as-cfo-discusses-her-struggle-with-disease/ /googles-porat-sees-ai-as-weapon-in-breast-cancer-war-as-cfo-discusses-her-struggle-with-disease/#respond Tue, 22 Oct 2019 20:59:26 +0000 /?p=13067 Google says it wants to be more than just a search engine for breast-cancer patients — a point  CFO Ruth Porat makes in a blog post in which she discusses her own struggles with the disease. The Alphabet Inc. company is investing in women’s health by developing artificial-intelligence tools that help with diagnosis and detection. […]

The post Google’s Porat Sees AI as Weapon in Breast Cancer War, as CFO Discusses Her Struggle With Disease appeared first on Karma.

]]> /googles-porat-sees-ai-as-weapon-in-breast-cancer-war-as-cfo-discusses-her-struggle-with-disease/feed/ 0 Alphabet, Amazon and Apple Push Hard into Healthcare, Leveraging Digital and Network Prowess /alphabet-amazon-and-apple-push-hard-into-healthcare-leveraging-digital-and-network-prowess/ /alphabet-amazon-and-apple-push-hard-into-healthcare-leveraging-digital-and-network-prowess/#respond Thu, 10 Oct 2019 21:21:30 +0000 /?p=12695 Key Takeaway: The world’s biggest tech firms, including Alphabet, Amazon and Apple, are using cutting edge digital technologies to build the future of healthcare, a more than $7 trillion opportunity.  For Kate Rosenbluth, then a neuroscientist at Stanford Neurosurgery Center, watching a man sob as he was told he couldn’t get surgery to control his […]

The post Alphabet, Amazon and Apple Push Hard into Healthcare, Leveraging Digital and Network Prowess appeared first on Karma.

]]> /alphabet-amazon-and-apple-push-hard-into-healthcare-leveraging-digital-and-network-prowess/feed/ 0 Color Adds Counseling to Genetic Services, With Eye Toward Better Healthcare for Underserved Groups /color-adds-counseling-to-genetic-services-with-eye-toward-better-healthcare-for-underserved-groups/ /color-adds-counseling-to-genetic-services-with-eye-toward-better-healthcare-for-underserved-groups/#respond Thu, 05 Sep 2019 15:34:40 +0000 /?p=11627 As sales of consumer genetic tests slow amid rising privacy concerns, Color Genomics has chosen a different path, by focusing on counseling services and selling to crowds overlooked by industry leaders 23andme and Ancestry.   Color, based in Burlingame, California, offers counseling to help users make sense of their test results. Such education is a critical […]

The post Color Adds Counseling to Genetic Services, With Eye Toward Better Healthcare for Underserved Groups appeared first on Karma.

]]> /color-adds-counseling-to-genetic-services-with-eye-toward-better-healthcare-for-underserved-groups/feed/ 0 Vasopharm to Sell Drug for Traumatic Brain Injury, An Overlooked Killer /vasopharm-to-sell-drug-for-traumatic-brain-injury-an-overlooked-killer/ /vasopharm-to-sell-drug-for-traumatic-brain-injury-an-overlooked-killer/#respond Fri, 12 Jul 2019 20:56:58 +0000 http://3.222.249.12/?p=10122 Germany’s Vasopharm raised $10.7 million as it plans to submit data for a clinical trial next year for its product that seeks to treat an issue with far-reaching social implications: traumatic brain injury.  Led by German PE firm HeidelbergCapital, the funding will help the company prepare for upcoming regulatory reviews of Ronopterin, which is in […]

The post Vasopharm to Sell Drug for Traumatic Brain Injury, An Overlooked Killer appeared first on Karma.

]]> /vasopharm-to-sell-drug-for-traumatic-brain-injury-an-overlooked-killer/feed/ 0 Eisai Tries to Bounce Back With New Dementia Approach /eisai-tries-to-bounce-back-with-new-dementia-approach/ /eisai-tries-to-bounce-back-with-new-dementia-approach/#respond Thu, 11 Jul 2019 20:47:13 +0000 http://3.222.249.12/?p=10097 Eisai Inc. opened an incubator for research into Alzheimer’s and other diseases as part of its new dementia research center, as it seeks to to bounce back from the failure of experimental drug aducanumab. Eisai’s new Genetics Guided Dementia Discovery (G2D2) Center, based in Cambridge, Massachusetts, will look to leverage its experience in genetics, data […]

The post Eisai Tries to Bounce Back With New Dementia Approach appeared first on Karma.

]]> /eisai-tries-to-bounce-back-with-new-dementia-approach/feed/ 0